FDA Orders Vision-Loss Warning on Ozempic, Zepbound and Other GLP-1 Drugs

The U.S. Food and Drug Administration will require warning labels on Ozempic, Zepbound and other GLP-1 medications about a possible risk of vision loss. The agency announced the decision on Monday. Novo Nordisk, Eli Lilly and AstraZeneca must all add the new information to their labels.

The warning covers nonarteritic anterior ischemic optic neuropathy, or NAION. It is a rare eye condition. The vision loss it causes is often permanent. Several medical studies have detected a link between taking one of the popular GLP-1 drugs and developing the condition.

Europe moved first. Regulators there already require the labels for Novo Nordisk's Ozempic, Rybelsus and Wegovy to list NAION as a "very rare" side effect.

Why is the FDA acting now?

Concerns about NAION surfaced earlier this fall. Reports emerged of patients suing Novo Nordisk and Eli Lilly. Both companies sell several GLP-1 drugs, which are primarily used to treat Type 2 diabetes and to produce weight loss.

The lawsuits and the studies behind them created pressure for U.S. action. Monday's FDA announcement converts that research into a formal labeling requirement across the entire drug class rather than a single product.

How big is the risk?

NAION is rare in the general population. An observational study published in July put its incidence at 8.5 per 10,000 people. That study also found the risk rises among men, people older than 50, and those with heart disease or other eye conditions.

Taking a GLP-1 is not the only risk factor. Some patients already carry elevated risk before they ever touch the drug. The predisposing factors include:

• A small optic disc
• Diabetes
• High blood pressure

There is one more pattern doctors watch. Experiencing NAION in one eye raises the risk that it will happen in the other eye.

What can patients do?

One practical step exists. A routine eye exam can determine whether a patient has a small optic disc, the key anatomical risk factor. Melinda Hakim, an ophthalmologist in Los Angeles, told MarketWatch in September that some patients get that exam before starting treatment with a GLP-1. That timing matters. It separates the risk that comes from a patient's own anatomy from any risk added by the drug.

Will the warning hurt sales?

Probably not, according to Wall Street. BMO Capital Markets analyst Evan David Seigerman said the regulatory change is not expected to affect GLP-1 usage in the United States. His reasoning rests on two points: the events are rare, and the increased risk relative to other diabetes therapies remains unclear.

"Given the limited incidence of events and unclear increased risk relative to other diabetes therapies, we expect today's GLP-1 labeling update is unlikely to temper incretin sales going forward," Seigerman wrote in a note to investors. "We emphasize the rarity of these events and continue to believe that use of GLP-1s under medical supervision remains extremely safe, with a favorable risk/benefit profile for patients."

What does this mean for the drugmakers?

The labeling change lands on the most commercially important drug class in the pharmaceutical industry. Novo Nordisk sells Ozempic, Rybelsus and Wegovy. Eli Lilly sells Zepbound and other GLP-1 products. AstraZeneca also markets medications in the class. All three companies now carry the same warning on every U.S. label.

The FDA's move aligns American labeling with the standard Europe set earlier, when Novo's three drugs gained "very rare" side-effect listings there. The pending patient lawsuits against Novo and Lilly remain the larger commercial question, because litigation outcomes, unlike label text, can carry financial consequences.

For patients already on the drugs, the practical takeaway from the FDA decision is narrower than the headline suggests: know your optic disc status, know your blood pressure, and treat the NAION risk as one number among many — 8.5 cases per 10,000 people — rather than a reason to stop therapy without consulting a doctor.